# Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus

> **NCT05314738** · PHASE1,PHASE2 · RECRUITING · sponsor: **Glaukos Corporation** · enrollment: 150 (estimated)

## Conditions studied

- Progressive Keratoconus

## Interventions

- **COMBINATION_PRODUCT:** NXL Energy 1
- **COMBINATION_PRODUCT:** NXL Energy 2
- **COMBINATION_PRODUCT:** NXL Energy 3
- **COMBINATION_PRODUCT:** Sham Treatment

## Key facts

- **NCT ID:** NCT05314738
- **Lead sponsor:** Glaukos Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-08
- **Primary completion:** 2025-08
- **Final completion:** 2026-02
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05314738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05314738, "Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05314738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*